JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v5i1.134ArticleDesensitization for the Prevention of Drug Hypersensitivityhttps://artdesignp.com/journal/JMDS/5/1/10.18063/jmds.v5i1.134YunJeong-Eun,JeongJiung,KangHye-Ryun2023512023-08-22Drug desensitization is a treatment strategy for patients with hypersensitivity to essential drugs without alternatives. The gradual increase in the drug dosage from low doses to therapeutic levels induces a transient immune tolerance to the culprit drug. Although desensitization has traditionally been recommended for IgE-mediated immediate hypersensitivity, this indication has recently been expanded to include non-IgE-mediated immediate responses, nonimmunological responses, and T-cell mediated delayed hypersensitivity reactions. Although the exact mechanism behind desensitization remains unclear, the process is thought to attenuate various intracellular signals in target cells through the high-affinity IgE receptor (FcɛRI) internalization, alteration in signaling pathways in mast cells and basophils, reduction in Ca2+ influx, and production of anti-drug IgG4 blocking antibody. Desensitization can be used for the safe administration of anti-neoplastic agents, antibiotics, aspirin, and nonsteroidal anti-inflammatory drugs. Various desensitization protocols have been proposed for each drug. The optimization of drug concentration, target dosage, administration interval, and route of administration is key to successful desensitization. In addition, the desensitization protocol should be individualized for each patient with consideration of the severity of the initial hypersensitivity response, the characteristics of the culprit drug, and the nature of the breakthrough reactions.Drug hypersensitivity, Desensitization, Antineoplastic agent, Antibiotics, Antitubercular agents

1. Mezzano V, Giavina-Bianchi P, Picard M, et al. Drug Desensitization In The Management Of Hypersensitivity Reactions To Monoclonal Antibodies And Chemotherapy. Biodrugs. 2014;28:133–144.2. Ring J, Gutermuth J. 100 Years of Hyposensitization: History of Allergen-Specific Immunotherapy (ASIT). Allergy. 2011;66:713–724.3. Widal MF, Abramin P, Lermoyez J. Anaphylaxie et Idiosyncrase [Anaphylaxis and Idiosyncracy]. Presse Med. 1922;30:189–193.4. O'Donovan WJ, Klorfajn I. Sensitivity to Penicillin; Anaphylaxis and Desensitization. Lancet. 1946;2:444–446.5. Vultaggio A, Nencini F, Bormioli S, et al. Desensitization Modulates Humoral and Cellular Immune Response to Infliximab in a Patient With an Immediate Hypersensitivity Reaction. J Allergy Clin Immunol Pract. 2020;8:1764–1767.6. Ang WX, Church AM, Kulis M, et al. Mast Cell Desensitization Inhibits Calcium Flux and Aberrantly Remodels Actin. J Clin Invest. 2016;126:4103–4118.7. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE Desensitization is Antigen Specific and Impairs Early and Late Mast Cell Responses Targeting FcεRI Internalization. Eur J Immunol. 2011;41:1004–1013.8. Mahajan A, Barua D, Cutler P, et al. Optimal Aggregation of FcεRI With a Structurally Defined Trivalent Ligand Overrides Negative Regulation Driven by Phosphatases. ACS Chem Biol. 2014;9:1508–1519.9. Shalit M, Levi-Schaffer F. Challenge of Mast Cells With Increasing Amounts of Antigen Induces Desensitization. Clin Exp Allergy. 1995;25:896–902.10. Andrews NL, Pfeiffer JR, Martinez AM, et al. Small, Mobile FcepsilonRI Receptor Aggregates are Signaling Competent. Immunity. 2009;31:469–479.11. Oka T, Rios EJ, Tsai M, et al. Rapid Desensitization Induces Internalization of Antigen-Specific IgE on Mouse Mast Cells. J Allergy Clin Immunol. 2013;132:922–932.12. Paolini R, Numerof R, Kinet JP. Phosphorylation/Dephosphorylation of High-Affinity IgE Receptors: A Mechanism for Coupling/Uncoupling a Large Signaling Complex. Proc Natl Acad Sci USA. 1992;89:10733–10737.13. Macglashan D, Miura K. Loss of SYK Kinase During IgE-Mediated Stimulation of Human Basophils. J Allergy Clin Immunol. 2004;114:1317–1324.14. Katz HR. Inhibitory Receptors and Allergy. Curr Opin Immunol. 2002;14:698–704.15. Lu-Kuo JM, Joyal DM, Austen KF, et al. Gp49b1 Inhibits IgE-Initiated Mast Cell Activation Through Both Immunoreceptor Tyrosine-Based Inhibitory Motifs, Recruitment of Src Homology 2 Domain-Containing Phosphatase-1, And Suppression of Early and Late Calcium Mobilization. J Biol Chem. 1999;274:5791–5796.16. Pichler WJ. Anaphylaxis to Drugs: Overcoming Mast Cell Unresponsiveness by Fake Antigens. Allergy. 2021;76:1340–1349.17. Naclerio R, Mizrahi EA, Adkinson NF Jr. Immunologic Observations During Desensitization and Maintenance of Clinical Tolerance to Penicillin. J Allergy Clin Immunol. 1983;71:294–301.18. Shamji MH, Kappen J, Abubakar-Waziri H, et al. Nasal Allergen-Neutralizing IgG4 Antibodies Block IgE-Mediated Responses: Novel Biomarker of Subcutaneous Grass Pollen Immunotherapy. J Allergy Clin Immunol. 2019;143:1067–1076.19. Vultaggio A, Matucci A, Nencini F, et al. Mechanisms of Drug Desensitization: Not Only Mast Cells. Front Pharmacol. 2020;11:590991.20. Teraki Y, Shiohara T. Successful Desensitization to Fixed Drug Eruption: The Presence of CD25+CD4+ T Cells in the Epidermis of Fixed Drug Eruption Lesions may be Involved in the Induction of Desensitization. Dermatology. 2004;209:29–32.21. Aydogan M, Yologlu N, Gacar G, et al. Successful Rapid Rituximab Desensitization in an Adolescent Patient With Nephrotic Syndrome: Increase in Number of Treg Cells After Desensitization. J Allergy Clin Immunol. 2013;132:478–480.22. Tuzer C, Sari M, Aktas Cetin E, et al. Rapid Drug Desensitization for Platinum-Based Chemotherapy Drugs Significantly Increases Peripheral Blood IL-10 Levels. Allergy. 2020;75:2942–2945.23. Lee AR, Kim SJ, Kim J, et al. Successful Desensitization for Antitubercular Drugs. Allergy Asthma Respir Dis. 2013;1:395–399.24. Yoon D, Ahn H, Kim SY, et al. Successful Rapid Desensitization to Trimethoprim-Sulfamethoxazole-Induced Delayed Hypersensitivity. Allergy Asthma Respir Dis. 2015;3:155–158.25. Heo YJ, Park SW, Lee KS, et al. Successful Desensitization to Fluconazole Induced Delayed Hypersensitivity: A Case Report. Allergy Asthma Respir Dis. 2018;6:68–71.26. Hong DIC. Desensitization for Allergic Reactions to Chemotherapy. Yonsei Med J. 2019;60:119–125.27. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity Reactions to Chemotherapy: Outcomes and Safety of Rapid Desensitization in 413 Cases. J Allergy Clin Immunol. 2008;122:574–580.28. Alvarez-Cuesta E, Madrigal-Burgaleta R, Broyles AD, et al. Standards for Practical Intravenous Rapid Drug Desensitization & Delabeling: A WAO Committee Statement. World Allergy Organ J. 2022;15:100640.29. Breslow RG, Caiado J, Castells MC. Acetylsalicylic Acid and Montelukast Block Mast Cell Mediator-Related Symptoms During Rapid Desensitization. Ann Allergy Asthma Immunol. 2009;102:155–160.30. Caiado J, Castells MC. Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis. Curr Allergy Asthma Rep. 2021;21:37.31. Seo JH, Jung J, Yoon JE, et al. A Successful Shortening of Desensitization Protocol in a Patient With Cetuximab Anaphylaxis. Allergy Asthma Respir Dis. 2022;10:181–185.32. Jung JW. Desensitization for Hypersensitivity Reactions Related to Chemotherapy. Allergy Asthma Respir Dis. 2020;8:105–106.33. Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016;4:497–504.34. Markman M, Kennedy A, Webster K, et al. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102–105.35. Lee CW, Matulonis UA, Castells MC. Rapid Inpatient/Outpatient Desensitization for Chemotherapy Hypersensitivity: Standard Protocol Effective in 57 Patients for 255 Courses. Gynecol Oncol. 2005;99:393–399.36. Markman M, Zanotti K, Peterson G, et al. Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity. J Clin Oncol. 2003;21:4611–4614.37. Lee EY, Jakubovic BD. Interleukin-6 and Cytokine Release Syndrome: A New Understanding in Drug Hypersensitivity Reactions. Ann Allergy Asthma Immunol. 2023;130:178–184.38. Lee SY, Yang MS, Jung JW, et al. Updates on Desensitization for Hypersensitivity Reactions Related to Chemotherapy. Allergy Asthma Respir Dis. 2013;1:295–302.39. Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al. Successful Parenteral Desensitization to Paclitaxel. J Allergy Clin Immunol. 1996;97:42–46.40. Tsao LR, Young FD, Otani IM, et al. Hypersensitivity Reactions to Platinum Agents and Taxanes. Clin Rev Allergy Immunol. 2022;62:432–448.41. Lee EJ, Kim YJ, Rhie SJ. Rituximab Infusion-Related Adverse Events and Risk Factors. Korean J Clin Pharm. 2013;23:223–231.42. Joo MH, Kim HJ, Ree YS, et al. Risk Factors of Infusion Related Reaction to Rituximab in Patients With Lymphoma. JPERM. 2018;10:60–67.43. Jung JW, Kang HR, Lee SH, et al. The Incidence and Risk Factors of Infusion Related Reactions to Rituximab for Treating B Cell Malignancy in a Single Tertiary Hospital. Oncology. 2014;86:127–134.44. Lee CW, Matulonis UA, Castells MC. Carboplatin Hypersensitivity: A 6-H 12-Step Protocol Effective in 35 Desensitizations in Patients With Gynecological Malignancies and Mast Cell/IgE-Mediated Reactions. Gynecol Oncol. 2004;95:370–376.45. Lee JH, Moon M, Kim YC, et al. A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol. J Allergy Clin Immunol Pract. 2020;8:696–703.46. Lee SH, Lee JH, Kim NH, et al. A Case of Rapid Desensitization for Rituximab-Induced Delayed Hypersensitivity Reaction. Allergy Asthma Respir Dis. 2019;7:109–112.47. Shin YS, Lee YW, Choi YH, et al. Spontaneous Reporting of Adverse Drug Events by Korean Regional Pharmacovigilance Centers. Pharmacoepidemiol Drug Saf. 2018;18:910–915.48. Kim HH, Seo J, Ahn YH, et al. Analysis of Breakthrough Reactions in 1,143 Desensitization Procedures in a Single Tertiary Hospital Using a One-Bag Desensitization Protocol. Front Allergy. 2022;3:786822.49. Park HK, Kang MG, Yang MS, et al. Epidemiology of Drug-Induced Anaphylaxis in a Tertiary Hospital in Korea. Allergol Int. 2017;66:557–562.50. Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a More Precise Diagnosis of Hypersensitivity to Beta-Lactams - An EAACI Position Paper. Allergy. 2020;75:1300–1315.51. Mayorga C, Celik G, Rouzaire P, et al. In Vitro Tests for Drug Hypersensitivity Reactions: An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy. 2016;71:1103–1134.52. Cernadas JR, Brockow K, Romano A, et al. General Considerations on Rapid Desensitization for Drug Hypersensitivity - A Consensus Statement. Allergy. 2010;65:1357–1366.53. Chastain DB, Hutzley VJ, Parekh J, et al. Antimicrobial Desensitization: A Review of Published Protocols. Pharmacy (Basel). 2019;7:112.54. Lin RY. Desensitization in the Management of Vancomycin Hypersensitivity. Arch Intern Med. 1990;150:2197–2198.55. Shadur B, Trahair TN, O'Brien T, et al. Desensitization to Liposomal Amphotericin B. J Allergy Clin Immunol Pract. 2017;5:181–183.56. Randolph C, Kaplan C, Fraser B. Rapid Desensitization to Fluconazole (Diflucan). Ann Allergy Asthma Immunol. 2008;100:616–617.57. Heo YJ, Park SW, Lee KS, et al. Successful Desensitization to Fluconazole Induced Delayed Hypersensitivity: A Case Report. Allergy Asthma Respir Dis. 2018;6:68–71.58. Jean T, Kwong K. Successful Desensitization of Voriconazole in an Immunosuppressed Pediatric Patient. J Allergy Clin Immunol Pract. 2015;3:637–638.59. Seki JT, Ng P, Lam W, et al. Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report. J Clin Med Res. 2017;9:725–728.60. Gonzalez-Estrada A, Fernandez J. Novel Valganciclovir Desensitization Protocol. Transplantation. 2014;98:50–51.61. Ladd AM, Martel-Laferriere V, Dieterich D. Successful Desensitization to Ribavirin in a Patient With Chronic Hepatitis C. J Clin Gastroenterol. 2012;46:716–717.62. Park JS. Korean Guidelines for the Treatment of Tuberculosis. Korean J Med. 2012;82:269–273.63. Kim HH, Moon M, Choi N, et al. Adverse Drug Reactions to First-Line Anti-Tubercular Drugs Based on Individual Case Safety Report in a Single Tertiary Hospital. Korean J Med. 2021;96:421–431.64. Kobashi Y, Abe T, Shigeto E, et al. Desensitization Therapy for Allergic Reactions to Antituberculous Drugs. Intern Med. 2010;49:2297–2301.65. Moon SD, Won HK, Cho JY, et al. Successful Readministration of Second-Line Antituberculous Agents in a Patient With Near-Fatal Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome. Allergy Asthma Respir Dis. 2015;3:297–301.66. Oh JH, Yun J, Yang MS, et al. Reintroduction of Antituberculous Drugs in Patients With Antituberculous Drug-Related Drug Reaction With Eosinophilia and Systemic Symptoms. J Allergy Clin Immunol Pract. 2021;9:3442–3449.67. Holland CL, Malasky C, Ogunkoya A, et al. Rapid Oral Desensitization to Isoniazid and Rifampin. Chest. 1990;98:1518–1519.68. Kim JH, Kim HB, Kim BS, et al. Rapid Oral Desensitization to Isoniazid, Rifampin, and Ethambutol. Allergy. 2003;58:540–541.69. Lee SY, Nam YH, Koh YI, et al. Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-Inflammatory Drugs. Allergy Asthma Immunol Res. 2019;11:212–221.70. Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of Chronic Urticaria Exacerbation by Aspirin. Curr Allergy Asthma Rep. 2005;5:277–283.71. Yeung WYW, Park HS. Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Med J. 2020;61:4–14.72. Cortellini G, Caruso C, Romano A. Aspirin Challenge and Desensitization: How, When and Why. Curr Opin Allergy Clin Immunol. 2017;17:247–254.73. Lee TH, Christie PE. Leukotrienes and Aspirin Induced Asthma. Thorax. 1993;48:1189–1190.74. Canto MG, Andreu I, Fernandez J, et al. Selective Immediate Hypersensitivity Reactions to NSAIDs. Curr Opin Allergy Clin Immunol. 2009;9:293–297.75. Wohrl S. NSAID Hypersensitivity - Recommendations for Diagnostic Work Up and Patient Management. Allergo J Int. 2018;27:114–121.76. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, et al. Tolerability to New COX-2 Inhibitors in NSAID-Sensitive Patients With Cutaneous Reactions. Ann Allergy Asthma Immunol. 2001;87:201–204.77. Cortellini G, Lippolis D, Amati S, et al. Effective Ibuprofen Desensitization in a Patient With Myopericarditis. Pharmacology. 2019;103:111–113.